Knowledge Center · Peptides

CJC-1295

GHRH analogNot FDA-approvedBanned in sport (WADA)

CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analog studied for its ability to raise growth hormone and IGF-1. Human data is limited; it is not FDA-approved.

On this pageOverviewWhat is it?MechanismEvidenceApplicationsWhat we knowWhat we don't knowRisksDiscuss with a providerFAQReferences

Overview

CJC-1295 is a synthetic analog of GHRH designed to stimulate the body's own growth-hormone release. A version (“with DAC”) extends its half-life. It is frequently paired with a ghrelin-receptor agonist such as Ipamorelin in research and optimization settings.

What is it?

A synthetic research peptide, not an approved medication, sold through research-supply channels.

Mechanism of Action

Mechanism:

  • GHRH-receptor agonism — stimulates the pituitary to release growth hormone in a more physiologic, pulsatile manner.
  • Downstream IGF-1 — increased GH can raise IGF-1.
  • DAC variant — binds albumin to extend duration of action.

Effects on GH/IGF-1 are biologically plausible and seen in early studies; long-term human outcome data is limited.

Current Scientific Evidence

Some early human pharmacology exists for GH/IGF-1 elevation; outcome and long-term safety data are limited.

Evidence typeStatus
Human pharmacologyEarly studies show GH/IGF-1 increases.
Long-term outcomes/safetyLimited human data.

Potential Clinical Applications (under investigation)

Studied around growth-hormone axis modulation. Not an approved treatment.

What We Know

  • It raises GH/IGF-1 via the GHRH receptor in early studies.
  • It is not FDA-approved and is prohibited in sport.

What We Don't Know

  • Long-term safety of sustained GH/IGF-1 elevation.
  • Optimal protocols and risk profile over time.

Potential Risks & Considerations

  • Sustained GH/IGF-1 elevation carries theoretical risks (e.g., fluid retention, insulin sensitivity, tissue growth).
  • Research-grade product quality.
  • Prohibited in sport (WADA).
  • Legal status varies.

Who May Wish to Discuss It With Their Provider

Growth-hormone-axis manipulation should only be considered with a licensed provider who can monitor labs and risks. This page is not a recommendation.

Frequently Asked Questions

What's the difference between CJC-1295 with and without DAC?

The DAC (Drug Affinity Complex) version binds albumin to extend its half-life and duration of action.

Is CJC-1295 FDA approved?

No.

Is it banned in sport?

Yes — GHRH analogs are prohibited under WADA.

Have questions about your own situation?

If you'd like help applying this information to your own health, schedule a consultation with the Bearing team.

Request a Consultation

Scientific References

  • Pharmacology literature on CJC-1295 / GHRH analogs — search PubMed.
  • WADA Prohibited List (peptide hormones, growth factors).

References are provided for further reading. Bearing summarizes the literature conservatively and updates pages as evidence evolves.

Related

Peptides: Ipamorelin · Sermorelin · Tools: Peptide Reconstitution Calculator

Educational disclaimer. This page is for general education and is not medical advice. It does not diagnose, treat, or recommend any substance. Many peptides are not FDA-approved; legal status varies and some are prohibited in sport. Discuss any decision with a licensed provider.